HK1159133A1 - Fgf-r4 receptor-specific antagonists fgf-r4 - Google Patents
Fgf-r4 receptor-specific antagonists fgf-r4Info
- Publication number
- HK1159133A1 HK1159133A1 HK11113762.6A HK11113762A HK1159133A1 HK 1159133 A1 HK1159133 A1 HK 1159133A1 HK 11113762 A HK11113762 A HK 11113762A HK 1159133 A1 HK1159133 A1 HK 1159133A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fgf
- receptor
- specific antagonists
- antagonists
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0803888A FR2933702A1 (fr) | 2008-07-08 | 2008-07-08 | Antagonistes specifiques du recepteur fgf-r4 |
| PCT/FR2009/051343 WO2010004204A2 (fr) | 2008-07-08 | 2009-07-07 | Antagonistes specifiques du recepteur fgf-r4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1159133A1 true HK1159133A1 (en) | 2012-07-27 |
Family
ID=40626849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11113762.6A HK1159133A1 (en) | 2008-07-08 | 2011-12-21 | Fgf-r4 receptor-specific antagonists fgf-r4 |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US20110150903A1 (el) |
| EP (1) | EP2315781B1 (el) |
| JP (2) | JP5726731B2 (el) |
| KR (1) | KR20110028536A (el) |
| CN (2) | CN103784954A (el) |
| AR (1) | AR072699A1 (el) |
| AU (1) | AU2009267834B2 (el) |
| BR (1) | BRPI0915660A2 (el) |
| CA (1) | CA2730300A1 (el) |
| CL (1) | CL2011000047A1 (el) |
| CO (1) | CO6440535A2 (el) |
| CR (1) | CR11868A (el) |
| CY (1) | CY1116847T1 (el) |
| DK (1) | DK2315781T3 (el) |
| DO (1) | DOP2011000005A (el) |
| EA (2) | EA201401107A1 (el) |
| EC (1) | ECSP11010748A (el) |
| ES (1) | ES2544761T3 (el) |
| FR (1) | FR2933702A1 (el) |
| HK (1) | HK1159133A1 (el) |
| HN (1) | HN2011000074A (el) |
| HR (1) | HRP20150836T1 (el) |
| HU (1) | HUE027221T2 (el) |
| IL (1) | IL210516A0 (el) |
| MA (1) | MA32547B1 (el) |
| MX (1) | MX2011000328A (el) |
| NI (1) | NI201100012A (el) |
| NZ (2) | NZ602905A (el) |
| PE (1) | PE20110313A1 (el) |
| PL (1) | PL2315781T3 (el) |
| PT (1) | PT2315781E (el) |
| SG (1) | SG10201403751XA (el) |
| SI (1) | SI2315781T1 (el) |
| TW (1) | TW201006492A (el) |
| UA (1) | UA107782C2 (el) |
| UY (1) | UY31970A (el) |
| WO (1) | WO2010004204A2 (el) |
| ZA (1) | ZA201100209B (el) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107090045A (zh) * | 2010-05-03 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 用于肿瘤诊断和治疗的组合物和方法 |
| US8906649B2 (en) | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
| EP2621950A4 (en) * | 2010-09-27 | 2015-09-02 | Janssen Biotech Inc | ANTIBODIES FOR BINDING HUMAN COLLAGEN II |
| KR20140021589A (ko) * | 2011-04-07 | 2014-02-20 | 제넨테크, 인크. | 항-fgfr4 항체 및 사용 방법 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| EP2723391B1 (en) * | 2011-06-24 | 2018-06-13 | University of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| IL292303A (en) | 2012-12-27 | 2022-06-01 | Ngm Biopharmaceuticals Inc | Methods of regulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2014105849A1 (en) * | 2012-12-28 | 2014-07-03 | Xoma (Us) Llc | Antibodies specific for fgfr4 and methods of use |
| WO2014165287A1 (en) * | 2013-03-12 | 2014-10-09 | The Translational Genomics Research Institute | Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4 |
| US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
| AU2014338549B2 (en) | 2013-10-25 | 2017-05-25 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| WO2015107171A1 (en) * | 2014-01-17 | 2015-07-23 | Sanofi | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody |
| JP6837840B2 (ja) | 2014-01-24 | 2021-03-10 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 結合タンパク質及びその使用方法 |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| TR201909951T4 (tr) | 2014-07-18 | 2019-07-22 | Sanofi Sa | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. |
| CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
| PL3180356T3 (pl) * | 2014-08-11 | 2020-04-30 | Daiichi Sankyo Europe Gmbh | Ludzkie przeciwciało anty-fgfr4 |
| WO2016054483A1 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2016151499A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
| EP3095465A1 (en) | 2015-05-19 | 2016-11-23 | U3 Pharma GmbH | Combination of fgfr4-inhibitor and bile acid sequestrant |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
| WO2017137503A1 (en) | 2016-02-10 | 2017-08-17 | Daiichi Sankyo Europe Gmbh | Combination of human anti-fgfr4 antibody and sorafenib |
| TW202409084A (zh) | 2016-03-04 | 2024-03-01 | 美商Ｊｎ生物科學有限責任公司 | 針對tigit之抗體 |
| US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| CA3042475C (en) | 2016-11-02 | 2024-01-16 | Novartis Ag. | Combinations of fgfr4 inhibitors and bile acid sequestrants |
| IL266769B2 (en) * | 2016-11-22 | 2024-04-01 | Merck Patent Gmbh | FGFR1-specific monoclonal antibodies and their preparation |
| EP3444275A1 (en) * | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
| CN109725159B (zh) * | 2018-12-28 | 2021-10-08 | 江苏众红生物工程创药研究院有限公司 | 人β2-微球蛋白的定量检测试纸卡与临床应用 |
| CN115551538A (zh) * | 2020-01-21 | 2022-12-30 | 拓维创新生物科技(香港)有限公司 | 干扰IL-1β受体信号转导的药剂 |
| PE20231078A1 (es) | 2020-06-02 | 2023-07-17 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| WO2022098662A2 (en) * | 2020-11-03 | 2022-05-12 | Twist Bioscience Corporation | Methods and compositions relating to chemokine receptor variants |
| CN118108840A (zh) * | 2022-11-29 | 2024-05-31 | 中国科学院深圳先进技术研究院 | 抗fgfr4单克隆抗体、靶向fgfr4的嵌合抗原受体t细胞及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| PT1242438E (pt) * | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
| ATE506077T1 (de) * | 2003-10-16 | 2011-05-15 | Imclone Llc | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
| WO2007136893A2 (en) * | 2006-02-10 | 2007-11-29 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
| JP5570218B2 (ja) * | 2006-11-03 | 2014-08-13 | ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｆｇｆｒ４抗体 |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| RU2009136669A (ru) * | 2007-03-09 | 2011-04-20 | Новартис АГ (CH) | Лечение меланомы |
-
2008
- 2008-07-08 FR FR0803888A patent/FR2933702A1/fr active Pending
-
2009
- 2009-07-07 EA EA201401107A patent/EA201401107A1/ru unknown
- 2009-07-07 UA UAA201101398A patent/UA107782C2/ru unknown
- 2009-07-07 WO PCT/FR2009/051343 patent/WO2010004204A2/fr active Application Filing
- 2009-07-07 DK DK09784478.1T patent/DK2315781T3/en active
- 2009-07-07 SI SI200931242T patent/SI2315781T1/sl unknown
- 2009-07-07 EA EA201170155A patent/EA021580B1/ru not_active IP Right Cessation
- 2009-07-07 NZ NZ602905A patent/NZ602905A/en not_active IP Right Cessation
- 2009-07-07 ES ES09784478.1T patent/ES2544761T3/es active Active
- 2009-07-07 MX MX2011000328A patent/MX2011000328A/es active IP Right Grant
- 2009-07-07 SG SG10201403751XA patent/SG10201403751XA/en unknown
- 2009-07-07 NZ NZ590860A patent/NZ590860A/xx not_active IP Right Cessation
- 2009-07-07 PE PE2011000015A patent/PE20110313A1/es not_active Application Discontinuation
- 2009-07-07 AU AU2009267834A patent/AU2009267834B2/en not_active Ceased
- 2009-07-07 KR KR1020117002857A patent/KR20110028536A/ko not_active Application Discontinuation
- 2009-07-07 CN CN201410084647.7A patent/CN103784954A/zh active Pending
- 2009-07-07 US US13/002,845 patent/US20110150903A1/en not_active Abandoned
- 2009-07-07 BR BRPI0915660A patent/BRPI0915660A2/pt not_active IP Right Cessation
- 2009-07-07 AR ARP090102534A patent/AR072699A1/es unknown
- 2009-07-07 CA CA2730300A patent/CA2730300A1/fr not_active Abandoned
- 2009-07-07 CN CN200980134842.3A patent/CN102149730B/zh not_active Expired - Fee Related
- 2009-07-07 PL PL09784478T patent/PL2315781T3/pl unknown
- 2009-07-07 HU HUE09784478A patent/HUE027221T2/en unknown
- 2009-07-07 EP EP09784478.1A patent/EP2315781B1/fr not_active Not-in-force
- 2009-07-07 PT PT97844781T patent/PT2315781E/pt unknown
- 2009-07-07 JP JP2011517203A patent/JP5726731B2/ja not_active Expired - Fee Related
- 2009-07-08 TW TW098123091A patent/TW201006492A/zh unknown
- 2009-07-08 UY UY0001031970A patent/UY31970A/es not_active Application Discontinuation
-
2010
- 2010-12-22 CR CR11868A patent/CR11868A/es not_active Application Discontinuation
-
2011
- 2011-01-06 IL IL210516A patent/IL210516A0/en unknown
- 2011-01-06 DO DO2011000005A patent/DOP2011000005A/es unknown
- 2011-01-07 EC EC2011010748A patent/ECSP11010748A/es unknown
- 2011-01-07 ZA ZA2011/00209A patent/ZA201100209B/en unknown
- 2011-01-07 CO CO11001540A patent/CO6440535A2/es active IP Right Grant
- 2011-01-07 HN HN2011000074A patent/HN2011000074A/es unknown
- 2011-01-07 CL CL2011000047A patent/CL2011000047A1/es unknown
- 2011-01-07 NI NI201100012A patent/NI201100012A/es unknown
- 2011-02-08 MA MA33595A patent/MA32547B1/fr unknown
- 2011-12-21 HK HK11113762.6A patent/HK1159133A1/xx not_active IP Right Cessation
-
2014
- 2014-10-17 JP JP2014212724A patent/JP2015057398A/ja active Pending
-
2015
- 2015-08-05 CY CY20151100681T patent/CY1116847T1/el unknown
- 2015-08-06 HR HRP20150836TT patent/HRP20150836T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1159133A1 (en) | Fgf-r4 receptor-specific antagonists fgf-r4 | |
| HUS2200025I1 (hu) | C5AR antagonisták | |
| IL219390A0 (en) | Il-17a antagonists | |
| IL195909A0 (en) | Pan-cell surface receptor-specific therapeutics | |
| HK1143994A1 (en) | Glucagon antagonists | |
| HK1203481A1 (en) | Glucagon antagonists | |
| EP2312947A4 (en) | TRPV4 Antagonist | |
| ZA200906812B (en) | Crig antagonists | |
| EP2277678A4 (en) | EXTERNAL COMPONENT | |
| EP2478011A4 (en) | FLUORINATED GHRH ANTAGONISTS | |
| HK1149205A1 (en) | Methods for inhibiting angiogenesis using egfl8 antagonists | |
| ZA201008177B (en) | Substituted quinazolines | |
| EP2365748A4 (en) | IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS | |
| GB0808944D0 (en) | Substituted quinazolines | |
| GB0808947D0 (en) | Substituted quinazolines | |
| GB0808967D0 (en) | Substitute quinazolines | |
| GB0808950D0 (en) | Substituted quinazolines | |
| GB0808951D0 (en) | Substituted quinazolines | |
| IL207438A0 (en) | 2-aminoquinolines as 5-ht5a receptor antagonists | |
| GB0810005D0 (en) | Substituted quinazolines | |
| GB0808953D0 (en) | substituted quinazolines | |
| GB0808952D0 (en) | Substituted quinazolines | |
| GB0808968D0 (en) | Substitute quinazolines | |
| GB2457363B (en) | Demarcation apparatus | |
| GB0701632D0 (en) | MET receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180707 |